The Multiple Myeloma Channel is supported with funding from BMS (Gold) and Legend Biotech (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASH 2025 | Novel strategies showing promise for high-risk multiple myeloma: combinations of T-cell engagers
Gareth Morgan, MD, PhD, FRCP, FRCPath, NYU Langone Health, New York City, NY, comments on novel strategies showing promise for high-risk multiple myeloma. He highlights the potential of combination therapy with T-cell engagers, such as teclistamab and daratumumab. This interview took place at the 67th ASH Annual Meeting and Exposition, held in Orlando, FL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
